Get the Stockscreener App
2.44
2.79%
-0.07
Editas Medicine Inc stock is traded at $2.44, with a volume of 1.62M.
It is down -2.79% in the last 24 hours and up +8.44% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$2.51
Open:
$2.48
24h Volume:
1.62M
Relative Volume:
0.67
Market Cap:
$204.26M
Revenue:
$32.31M
Net Income/Loss:
$-237.09M
P/E Ratio:
-0.8472
EPS:
-2.88
Net Cash Flow:
$-219.11M
1W Performance:
-22.54%
1M Performance:
+8.44%
6M Performance:
+86.26%
1Y Performance:
-52.53%
1-Day Range:
$2.37
$2.49
1-Week Range:
$2.37
$3.19
52-Week Range:
$0.9101
$5.085
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.44 | 210.12M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Is Editas Medicine Inc. a growth stock or a value stockPre Market Picks With High Returns - jammulinksnews.com
What are analysts’ price targets for Editas Medicine Inc. in the next 12 monthsReal Time Watchlist To Watch Now - jammulinksnews.com
What is the dividend policy of Editas Medicine Inc. stockTop Growth Alerts With Proven Results - jammulinksnews.com
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? - Yahoo Finance
Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday - MarketBeat
Editas MedicinePrimed For An Unlikely Comeback? It's Not Impossible - Seeking Alpha
EDIT SEC FilingsEditas Medicine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Editas Medicine Inc. Flashes Buy Signal on Multi Timeframe ChartChart Driven High Reward Trading Setup Presented - metal.it
Published on: 2025-07-29 18:14:10 - metal.it
Published on: 2025-07-29 11:06:01 - metal.it
Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Gene Editing Market Exclusive Report with Detailed Study - openPR.com
What is Editas Medicine Inc. company’s growth strategyFree Stock Index Interpretation - jammulinksnews.com
Does Editas Medicine Inc. stock perform well during market downturnsHigh-velocity capital appreciation - jammulinksnews.com
Why is Editas Medicine Inc. stock attracting strong analyst attentionMaximize returns with smart investment plans - jammulinksnews.com
What catalysts could drive Editas Medicine Inc. stock higher in 2025Invest confidently with daily market forecasts - jammulinksnews.com
Should I hold or sell Editas Medicine Inc. stock in 2025Identify breakout stocks before they peak - jammulinksnews.com
Is Editas Medicine Inc. stock overvalued or undervaluedUnlock daily market insights for better decisions - jammulinksnews.com
What drives Editas Medicine Inc. stock priceTriple-digit profit margins - PrintWeekIndia
Will Editas Medicine Inc. stock split in the near futureConsistent triple-digit returns - jammulinksnews.com
Can Editas Medicine Inc. stock recover from recent declineFree Stock Market Forecast Reports - jammulinksnews.com
What analysts say about Editas Medicine Inc. stockBreakout stock performance - Autocar Professional
What drives Avanos Medical Inc. stock priceExplosive market performance - jammulinksnews.com
Editas Medicine Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com
Is Editas Medicine Inc. a good long term investmentExceptional profit margins - Autocar Professional
There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump - simplywall.st
What makes Editas Medicine Inc. stock price move sharplyVerified Return Tips - beatles.ru
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):